Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107

Malvezzi, 2012, European cancer mortality predictions for the year 2012, Ann Oncol, 23, 1044, 10.1093/annonc/mds024

Wakelee, 2007, Lung cancer incidence in never smokers, J Clin Oncol, 25, 472, 10.1200/JCO.2006.07.2983

Edwards, 2005, Annual report to the nation on the status of cancer 1975–2002, featuring population-based trends in cancer treatment, J Natl Cancer Inst, 97, 1407, 10.1093/jnci/dji289

Toh, 2006, Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity, J Clin Oncol, 24, 2245, 10.1200/JCO.2005.04.8033

Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society. European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221

Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, 3, 75ra26, 10.1126/scitranslmed.3002003

Rekhtman, 2012, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations, Clin Cancer Res, 18, 1167, 10.1158/1078-0432.CCR-11-2109

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448

Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993

Yi, 2012, Detection of Anaplastic Lymphoma Kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review, Mol Diagn Ther, 16, 143, 10.1007/BF03262202

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Ardizzoni, 2007, Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J Natl Cancer Inst, 99, 847, 10.1093/jnci/djk196

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5

Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466

Lima, 2011, Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis, PLoS One, 6, e22681, 10.1371/journal.pone.0022681

Soria, 2010, Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC), Ann Oncol, 21, viii147

Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9

Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 13, 33, 10.1016/S1470-2045(11)70318-7

Pujol, 2006, Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials, Lung Cancer, 51, 335, 10.1016/j.lungcan.2005.11.001

Park, 2007, Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5233, 10.1200/JCO.2007.10.8134

Gridelli, 2004, Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel, Ann Oncol, 15, 419, 10.1093/annonc/mdh087

1999, The elderly lung cancer vinorelbine Italian Study Group, J Natl Cancer Inst, 91, 66

Lilenbaum, 2009, Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials, J Thorac Oncol, 4, 869, 10.1097/JTO.0b013e3181a9a020

Quoix, 2011, Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial, Lancet, 378, 1079, 10.1016/S0140-6736(11)60780-0

Lilenbaum, 2012, A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2, J Clin Oncol 30, 30

Gridelli, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial, J Natl Cancer Inst, 95, 362, 10.1093/jnci/95.5.362

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Shaw, 2011, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, Lancet Oncol, 12, 1004, 10.1016/S1470-2045(11)70232-7

Robinet, 2001, Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1, Ann Oncol, 12, 59, 10.1023/A:1008338312647

Porta, 2011, Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur Respir J, 37, 624, 10.1183/09031936.00195609

Cappuzzo, 2010, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 521, 10.1016/S1470-2045(10)70112-1

Zhang, 2011, Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis, Chest, 140, 117, 10.1378/chest.10-2745

Paz-Ares, 2012, J Clin Oncol, 30, 10.1200/JCO.2011.39.7646

Paz-Ares, 2012, Lancet Oncol, 13, 247, 10.1016/S1470-2045(12)70063-3

Di Maio, 2009, Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer, J Clin Oncol, 27, 1836, 10.1200/JCO.2008.17.5844

Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163

Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753

Ciuleanu, 2012, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study, Lancet Oncol, 13, 300, 10.1016/S1470-2045(11)70385-0

Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4

Vamvakas, 2010, Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.7519

Lynch, 1996, Optimal therapy of malignant pleural effusions, Int J Oncol, 8

Dresler, 2005, Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion, Chest, 127, 909, 10.1378/chest.127.3.909

Rosen, 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial, Cancer, 100, 2613, 10.1002/cncr.20308

Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304

Temel, 2010, Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 363, 733, 10.1056/NEJMoa1000678

Tanvetyanon, 2008, Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol, 26, 1142, 10.1200/JCO.2007.14.2091

Gaspar, 2010, The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 96, 17, 10.1007/s11060-009-0060-9

Aoyama, 2006, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 295, 2483, 10.1001/jama.295.21.2483

Andrews, 2004, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 363, 1665, 10.1016/S0140-6736(04)16250-8

Mordant, 2012, Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?, Eur J Cardiothorac Surg, 41, 617, 10.1093/ejcts/ezr042

Pfannschmidt, 2010, Surgical treatment of oligometastatic non-small cell lung cancer, Lung Cancer, 69, 251, 10.1016/j.lungcan.2010.05.003